Loading...
•
Dec 31, 2023
Cencora Q1 2024 Earnings Report
Cencora reported strong first quarter results, with revenue up 15.0% year-over-year and adjusted diluted EPS increasing by 21.0%.
Key Takeaways
Cencora's first quarter fiscal year 2024 showed strong performance with a 15.0% increase in revenue to $72.3 billion. GAAP diluted EPS was $2.98, while adjusted diluted EPS increased to $3.28. The company has raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.25 to $13.50.
Revenue increased by 15.0% year-over-year to $72.3 billion.
GAAP diluted EPS was $2.98, compared to $2.33 in the prior year.
Adjusted diluted EPS increased by 21.0% to $3.28.
Adjusted diluted EPS guidance raised to $13.25 to $13.50 for fiscal year 2024.
Cencora
Cencora
Forward Guidance
Cencora updated its fiscal year 2024 financial guidance to reflect its expected strong business performance for the full fiscal year, including the incremental contributions from commercial COVID-19 vaccine distribution in the first quarter.
Positive Outlook
- Revenue growth to be in the range of 10 to 12 percent, up from the previous range of 7 to 10 percent
- U.S. Healthcare Solutions revenue growth to be in the range of 11 to 13 percent, up from the previous range of 7 to 10 percent
- Adjusted diluted earnings per share to be in the range of $13.25 to $13.50, up from the previous range of $12.70 to $13.00
- Adjusted consolidated operating income growth to be in the range of 8 to 10 percent, up from the previous range of 4 to 6 percent
- International Healthcare Solutions segment operating income growth to be in the range of 5 to 8 percent, up from the previous range of 1 to 4 percent
Challenges Ahead
- The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available or cannot be reasonably estimated.
- LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company’s control
- acquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.
- the timing and amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable and cannot be reasonably estimated.
- The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable and cannot be reasonably estimated.